EPS for Marrone Bio Innovations, Inc. (MBII) Expected At $-0.04

July 14, 2018 - By Robert Reynolds

Marrone Bio Innovations, Inc. (NASDAQ:MBII) LogoInvestors sentiment increased to 5.5 in Q1 2018. Its up 4.93, from 0.57 in 2017Q4. It improved, as 1 investors sold Marrone Bio Innovations, Inc. shares while 1 reduced holdings. 6 funds opened positions while 5 raised stakes. 78.12 million shares or 565.72% more from 11.74 million shares in 2017Q4 were reported.
Bluecrest Capital Management Ltd stated it has 12,428 shares. Commercial Bank Of America Corp De invested in 0% or 10,102 shares. Blackrock reported 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Guggenheim Capital Limited Liability Corp has 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII). Ogorek Anthony Joseph Ny Adv accumulated 300 shares. Waddell And Reed Inc has 0.11% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 24.71 million shares. Primecap Mngmt Communications Ca holds 0% of its portfolio in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 2.63M shares. Ardsley Advisory Prns has invested 1.91% in Marrone Bio Innovations, Inc. (NASDAQ:MBII). State Street Corp has 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 10,800 shares. Barclays Plc holds 0% in Marrone Bio Innovations, Inc. (NASDAQ:MBII) or 20,200 shares. Capital Planning Advsrs Limited Liability Com holds 33,079 shares or 0.02% of its portfolio. Hanson Mcclain reported 10,000 shares or 0% of all its holdings. Vanguard Group owns 0% invested in Marrone Bio Innovations, Inc. (NASDAQ:MBII) for 1.05 million shares. Northern Corp, a Illinois-based fund reported 31,936 shares. 2,000 were accumulated by Carroll Fin Incorporated.

Since February 5, 2018, it had 1 insider buy, and 0 insider sales for $5.00 million activity.

Analysts expect Marrone Bio Innovations, Inc. (NASDAQ:MBII) to report $-0.04 EPS on August, 13.They anticipate $0.21 EPS change or 84.00 % from last quarter’s $-0.25 EPS. After having $-0.04 EPS previously, Marrone Bio Innovations, Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.52% or $0.01 during the last trading session, reaching $1.92. About 174,618 shares traded. Marrone Bio Innovations, Inc. (NASDAQ:MBII) has risen 48.33% since July 14, 2017 and is uptrending. It has outperformed by 35.76% the S&P500.

Marrone Bio Innovations, Inc. provides bio pest management and plant health products primarily for agricultural and water markets in the United States and internationally. The company has market cap of $212.10 million. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. It currently has negative earnings. The company's products include Regalia, a plant extract fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants.

More important recent Marrone Bio Innovations, Inc. (NASDAQ:MBII) news were published by: Investorideas.com which released: “(NASDAQ: $MBII) News: Grandevo┬« CG and Venerate┬« CG for Pest Insect and Mite Control Cleared for Use on …” on June 28, 2018, also Nasdaq.com published article titled: “Marrone Bio Innovations to Host Virtual Roadshow Webinar on July 26th, 2018”, Globenewswire.com published: “Marrone Bio Innovations Joins the Russell 2000 Index” on June 25, 2018. More interesting news about Marrone Bio Innovations, Inc. (NASDAQ:MBII) was released by: Bizjournals.com and their article: “Why Marrone Bio is sponsoring a cannabis-growing competition” with publication date: June 20, 2018.

Marrone Bio Innovations, Inc. (NASDAQ:MBII) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.